Table 1.
Demographic, virological and immunological data for the entire population and the R5 and X4 subgroups, as identified by genotyping at T1
| All patients | R5 subgroup patients | X4 subgroup patients | p | |
|---|---|---|---|---|
| Number |
219 |
146 |
73 |
ns |
| Male (n) |
173 |
118 |
55 |
ns |
| Italian (n) |
180 |
114 |
66 |
ns |
| Agea (years) |
41 (19–79) |
40 (19–74) |
43 (21–79) |
p= 0.0332 |
|
Riskb |
|
|
|
|
| Heterosexual (n) |
91 |
60 |
31 |
ns |
| MSM (n) |
67 |
47 |
20 |
ns |
| Drug user (n) |
18 |
11 |
7 |
ns |
| Missing (n) |
43 |
28 |
15 |
ns |
| Subtype-B (n) |
171 |
113 |
56 |
ns |
| Primarycn (%) |
29 (13.2%) |
21 (14.3%) |
8 (11%) |
Ns |
| T0 CD4 cells/mm3a |
260 (0–1090) |
284 (0–810) |
201 (7–1090) |
p= 0.0216 |
| T0 CD4%a |
16 (0–39) |
17 (0–37) |
13 (1–39) |
ns |
| T0 HIV RNAa copies/ml |
101836 (412–1x107) |
101836 (412–1x107) |
1000182 (547–6258236) |
ns |
| T0 HIV DNAa, d |
1198 (33–70123) |
1185 (70–18856) |
1297 (33–70123) |
ns |
| T1 CD4 cells/mm3a |
560 (54–1330) |
580 (54–1306) |
485 (96–1330) |
ns |
| T1 CD4%a |
28.9 (3.4–55.2) |
29.9 (3.4–55,2) |
26 (5–51.9) |
ns |
| T1 HIV RNA<2,5 copies/ml n (%) |
83 (37.9%) |
62 (42.4%) |
21 (28.7%) |
ns |
| T1 HIV DNAa, d | 107 (5–892) | 105 (5–892) | 110 (5–740) | ns |
aExpressed as median and range.
bTransmission risk reported as prevalent.
c Being in HIV Primary Infection at the start of therapy.
d Copies/106PBMCs.